Brainstorm Cell Therapeutics Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Brainstorm Cell Therapeutics stock.
View analyst ratings for Brainstorm Cell Therapeutics or view top-rated stocks.

Wall Street analysts have given Brainstorm Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brainstorm Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Brainstorm Cell Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 3,670,000 shares, a decline of 16.4% from the March 31st total of 4,390,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is currently 3.2 days.
View Brainstorm Cell Therapeutics' Short Interest.

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its earnings results on Sunday, April, 25th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.07.
View Brainstorm Cell Therapeutics' earnings history.

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has decreased by 49.4% and is now trading at $3.38.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 12-month target prices for Brainstorm Cell Therapeutics' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 255.0% from the stock's current price.
View analysts' price targets for Brainstorm Cell Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Brainstorm Cell Therapeutics include Aptose Biosciences (APTO), Oyster Point Pharma (OYST), Gritstone bio (GRTS), AVROBIO (AVRO), Codiak BioSciences (CDAK), Jounce Therapeutics (JNCE), Solid Biosciences (SLDB), Lineage Cell Therapeutics (LCTX), Outlook Therapeutics (OTLK), Opthea (OPT), Adverum Biotechnologies (ADVM), Fusion Pharmaceuticals (FUSN), Surface Oncology (SURF), SQZ Biotechnologies (SQZ) and Autolus Therapeutics (AUTL).
View all of BCLI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Isoray (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.38%), JPMorgan Chase & Co. (2.22%), Geode Capital Management LLC (1.32%), Northern Trust Corp (0.82%), Phoenix Holdings Ltd. (0.16%) and Weaver Consulting Group (0.14%). Company insiders that own Brainstorm Cell Therapeutics stock include David Setboun, International Holdings Ltd Acc, Irit Arbel, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends for Brainstorm Cell Therapeutics.

BCLI stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Aptus Capital Advisors LLC, Alliancebernstein L.P., and Northern Trust Corp.
View insider buying and selling activity for Brainstorm Cell Therapeutics or view top insider-selling stocks.

BCLI stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Geode Capital Management LLC, Weaver Consulting Group, BlackRock Inc., GSA Capital Partners LLP, Barclays PLC, HighTower Advisors LLC, and New York State Common Retirement Fund. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include David Setboun, Preetam Shah, Ralph Dr Kern, and Sankesh Abbhi.
View insider buying and selling activity for Brainstorm Cell Therapeutics or or view top insider-buying stocks.

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCLI stock can currently be purchased for approximately $3.38.

Brainstorm Cell Therapeutics has a market capitalization of $122.76 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

Brainstorm Cell Therapeutics employs 39 workers across the globe.

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

Brainstorm Cell Therapeutics is headquartered at 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]